A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG)
Abstract Objective To investigate the prevalence of histopathological subtypes, the clinical stage at presentation and treatment modalities in Polish patients with orbital lymphoma (OL) and to determine prognostic outcomes. Methods The retrospective study of 107 patients with OL treated in a 14‐year...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5223 |
| _version_ | 1797903108544659456 |
|---|---|
| author | Elżbieta Kalicińska Agnieszka Giza Jan Maciej Zaucha Sebastian Giebel Dagmara Zimowska‐Curyło Iga Andrasiak Wojciech Spychałowicz Jerzy Wojnar Andrzej Balcerzak Joanna Romejko‐Jarosińska Ewa Paszkiewicz‐Kozik Wanda Knopińska‐Posłuszny Justyna Rybka Paula Jabłonowska Tomasz Wróbel |
| author_facet | Elżbieta Kalicińska Agnieszka Giza Jan Maciej Zaucha Sebastian Giebel Dagmara Zimowska‐Curyło Iga Andrasiak Wojciech Spychałowicz Jerzy Wojnar Andrzej Balcerzak Joanna Romejko‐Jarosińska Ewa Paszkiewicz‐Kozik Wanda Knopińska‐Posłuszny Justyna Rybka Paula Jabłonowska Tomasz Wróbel |
| author_sort | Elżbieta Kalicińska |
| collection | DOAJ |
| description | Abstract Objective To investigate the prevalence of histopathological subtypes, the clinical stage at presentation and treatment modalities in Polish patients with orbital lymphoma (OL) and to determine prognostic outcomes. Methods The retrospective study of 107 patients with OL treated in a 14‐year period in Polish hematological centers. The analysis included histopathological subtype, disease clinical advancement, treatment modalities, progression‐free survival (PFS), and overall survival (OS). Results The median patient age was 60 years (range 51–71). Mucosa‐associated lymphoid tissue (MALT) lymphoma accounted for slightly more than half of all cases of orbital lymphoma (51%). The second most common subtype was diffuse large B‐cell lymphoma (DLBCL) (29%). Primary orbital lymphoma was diagnosed in 48% of all patients. According to the Ann Arbor, localized stage IE of orbital lymphoma was diagnosed only in 39% of all patients. Systemic involvement was observed in more than half of all patients (52%). The median follow‐up period was 30 months (range 0–160 months). Patients with non‐MALT lymphoma had a significantly inferior PFS compared to patients with MALT lymphoma, (p = 0.047). Patients with primary orbital lymphoma had a superior PFS compared to patients with secondary orbital lymphoma [median PFS 104.5 months vs. 33.4 months], (p = 0.069). Younger patients with MALT lymphoma were characterized by superior PFS (median PFS not reached) compared to other studied subgroups of patients (older patients with MALT lymphoma, younger and older non‐MALT lymphoma patients) with a median PFS of 30.5, 32.2, 32.6 months respectively (p = 0.039). Patients treated with chemotherapy alone had inferior PFS compared to patients treated with combined therapies (p = 0.034). The median PFS across patients who received chemotherapy alone was 23.7 months, whereas across other patients was 73.9 months. Conclusions Secondary lymphoma accounts for more than half of the orbital lymphoma in Polish population. The advanced clinical stage of the disease (non‐IE according to Ann Arbor) concerns two‐thirds of the overall population of patients with orbital lymphomas and one‐third of MALT lymphoma patients. The high incidence of advanced stages of orbital lymphoma may indicate the need for combined treatment. Combined orbital lymphoma treatment is associated with superior PFS compared to chemotherapy alone in overall population of patients with orbital lymphoma. |
| first_indexed | 2024-04-10T09:27:46Z |
| format | Article |
| id | doaj.art-8bfcff17849f4c5cb3b258376f77adc4 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T09:27:46Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-8bfcff17849f4c5cb3b258376f77adc42023-02-19T18:54:07ZengWileyCancer Medicine2045-76342023-02-011233036304510.1002/cam4.5223A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG)Elżbieta Kalicińska0Agnieszka Giza1Jan Maciej Zaucha2Sebastian Giebel3Dagmara Zimowska‐Curyło4Iga Andrasiak5Wojciech Spychałowicz6Jerzy Wojnar7Andrzej Balcerzak8Joanna Romejko‐Jarosińska9Ewa Paszkiewicz‐Kozik10Wanda Knopińska‐Posłuszny11Justyna Rybka12Paula Jabłonowska13Tomasz Wróbel14Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation Wrocław Medical University Wrocław PolandDepartment of Hematology Jagiellonian University Medical College Kraków PolandDepartment of Hematology and Transplantology Medical University of Gdańsk Gdańsk PolandDepartment of Bone Marrow Transplantation and Oncohematology Maria Sklodowska‐Curie National Research Institute of Oncology Gliwice PolandDepartment of Hematology Jagiellonian University Medical College Kraków PolandIndependent Researcher Wrocław PolandDepartment of Internal Medicine and Oncology Silesian Medical University Katowice PolandDepartment of Internal Medicine and Oncology Silesian Medical University Katowice PolandDepartment of Hematology and Bone Marrow Transplantation Poznan University of Medical Science Poznań PolandMaria Sklodowska‐Curie National Research Institute of Oncology Warsaw PolandMaria Sklodowska‐Curie National Research Institute of Oncology Warsaw PolandDepartment of Hematology and Bone Marrow Transplantation Maritime Hospital Gdynia PolandDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation Wrocław Medical University Wrocław PolandDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation Wrocław Medical University Wrocław PolandDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation Wrocław Medical University Wrocław PolandAbstract Objective To investigate the prevalence of histopathological subtypes, the clinical stage at presentation and treatment modalities in Polish patients with orbital lymphoma (OL) and to determine prognostic outcomes. Methods The retrospective study of 107 patients with OL treated in a 14‐year period in Polish hematological centers. The analysis included histopathological subtype, disease clinical advancement, treatment modalities, progression‐free survival (PFS), and overall survival (OS). Results The median patient age was 60 years (range 51–71). Mucosa‐associated lymphoid tissue (MALT) lymphoma accounted for slightly more than half of all cases of orbital lymphoma (51%). The second most common subtype was diffuse large B‐cell lymphoma (DLBCL) (29%). Primary orbital lymphoma was diagnosed in 48% of all patients. According to the Ann Arbor, localized stage IE of orbital lymphoma was diagnosed only in 39% of all patients. Systemic involvement was observed in more than half of all patients (52%). The median follow‐up period was 30 months (range 0–160 months). Patients with non‐MALT lymphoma had a significantly inferior PFS compared to patients with MALT lymphoma, (p = 0.047). Patients with primary orbital lymphoma had a superior PFS compared to patients with secondary orbital lymphoma [median PFS 104.5 months vs. 33.4 months], (p = 0.069). Younger patients with MALT lymphoma were characterized by superior PFS (median PFS not reached) compared to other studied subgroups of patients (older patients with MALT lymphoma, younger and older non‐MALT lymphoma patients) with a median PFS of 30.5, 32.2, 32.6 months respectively (p = 0.039). Patients treated with chemotherapy alone had inferior PFS compared to patients treated with combined therapies (p = 0.034). The median PFS across patients who received chemotherapy alone was 23.7 months, whereas across other patients was 73.9 months. Conclusions Secondary lymphoma accounts for more than half of the orbital lymphoma in Polish population. The advanced clinical stage of the disease (non‐IE according to Ann Arbor) concerns two‐thirds of the overall population of patients with orbital lymphomas and one‐third of MALT lymphoma patients. The high incidence of advanced stages of orbital lymphoma may indicate the need for combined treatment. Combined orbital lymphoma treatment is associated with superior PFS compared to chemotherapy alone in overall population of patients with orbital lymphoma.https://doi.org/10.1002/cam4.5223head and neck cancerMALTOcular adnexal lymphomaprognosis |
| spellingShingle | Elżbieta Kalicińska Agnieszka Giza Jan Maciej Zaucha Sebastian Giebel Dagmara Zimowska‐Curyło Iga Andrasiak Wojciech Spychałowicz Jerzy Wojnar Andrzej Balcerzak Joanna Romejko‐Jarosińska Ewa Paszkiewicz‐Kozik Wanda Knopińska‐Posłuszny Justyna Rybka Paula Jabłonowska Tomasz Wróbel A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG) Cancer Medicine head and neck cancer MALT Ocular adnexal lymphoma prognosis |
| title | A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG) |
| title_full | A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG) |
| title_fullStr | A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG) |
| title_full_unstemmed | A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG) |
| title_short | A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG) |
| title_sort | survey across orbital lymphoma in poland multicenter retrospective study of polish lymphoma research group plrg |
| topic | head and neck cancer MALT Ocular adnexal lymphoma prognosis |
| url | https://doi.org/10.1002/cam4.5223 |
| work_keys_str_mv | AT elzbietakalicinska asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT agnieszkagiza asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT janmaciejzaucha asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT sebastiangiebel asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT dagmarazimowskacuryło asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT igaandrasiak asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT wojciechspychałowicz asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT jerzywojnar asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT andrzejbalcerzak asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT joannaromejkojarosinska asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT ewapaszkiewiczkozik asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT wandaknopinskaposłuszny asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT justynarybka asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT paulajabłonowska asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT tomaszwrobel asurveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT elzbietakalicinska surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT agnieszkagiza surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT janmaciejzaucha surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT sebastiangiebel surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT dagmarazimowskacuryło surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT igaandrasiak surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT wojciechspychałowicz surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT jerzywojnar surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT andrzejbalcerzak surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT joannaromejkojarosinska surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT ewapaszkiewiczkozik surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT wandaknopinskaposłuszny surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT justynarybka surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT paulajabłonowska surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg AT tomaszwrobel surveyacrossorbitallymphomainpolandmulticenterretrospectivestudyofpolishlymphomaresearchgroupplrg |